The aversive, anxiolytic-like, and verapamil-sensitive psychostimulant effects of pulegone

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 5, 2014, Pages 771-778

  Silveira, Nayara Santos Da ^a   De Oliveira Silva, Grasielle Lopes ^a   De Lamanes, Bianca Freitas ^a   Prado, Ligia Carolina Da Silva ^a   Bispo da Silva, Luiz Borges ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Behavior; Diltiazem; Menthol; Pulegone; Verapamil

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; CALCIUM CHANNEL L TYPE; DILTIAZEM; FLUMAZENIL; HALOPERIDOL; MENTHOL; PICROTOXIN; PULEGONE; VERAPAMIL; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; TERPENE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVERSIVE BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENTIATION; ELEVATED PLUS MAZE TEST; EXPERIMENTAL TEST; GRASPING TEST; GROOMING; IMMOBILIZATION; LOCOMOTION; MALE; MOTOR COORDINATION; MOTOR INCOORDINATION; MOUSE; MUSCLE STRENGTH; NONHUMAN; OPEN FIELD BEHAVIOR; PLACE PREFERENCE; PREDICTION; PSYCHOSTIMULANT EFFECT; REARING; REWARD; REWARDING EFFECT; ROTAROD TEST; TRANQUILIZING ACTIVITY; WEAKNESS; ANIMAL; CONDITIONING; DECISION MAKING; DRUG EFFECTS; DRUG INTERACTION; HAND STRENGTH; MAZE TEST; MOTOR ACTIVITY; REINFORCEMENT;

ANIMALS; ANTI-ANXIETY AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; CONDITIONING (PSYCHOLOGY); DILTIAZEM; DRUG INTERACTIONS; FLUMAZENIL; GROOMING; HALOPERIDOL; HAND STRENGTH; MALE; MAZE LEARNING; MENTHOL; MICE; MONOTERPENES; MOTOR ACTIVITY; PICROTOXIN; REINFORCEMENT (PSYCHOLOGY); ROTAROD PERFORMANCE TEST; VERAPAMIL;

EID: 84899858350     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00832     Document Type: Article

References (49)

1. Beikmohammadi M. The Evaluation of Medicinal Properties of Ziziphora clinopodioides. World Applied Science Journal, 12, 1635-1638 (2011).
2. European Food Safety Authority. Compendium of botanicals that have been reported to contain toxic, addictive, psychotropic or other substances of concern on request of EFSA. EFSA Journal, 7, 100 (2009).
3. Petrakis EA, Kimbaris AC, Pappas CS, Tarantilis PA, Polissiou MG. Quantitative determination of pulegone in pennyroyal oil by FT-IR spectroscopy. J. Agric. Food Chem., 57, 10044-10048 (2009).
4. Umezu T, Sakata A, Ito H. Ambulation-promoting effect of peppermint oil and identification of its active constituents. Pharmacol. Biochem. Behav., 69, 383-390 (2001).
5. Anderson IB, Mullen WH, Meeker JE, Khojasteh-Bakht SC, Oishi S, Nelson SD, Blanc PD. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann. Intern. Med., 124, 726-734 (1996).
6. Nath SS, Pandey C, Roy D. A near fatal case of high dose peppermint oil ingestion - Lessons learnt. Indian J. Anaesth., 56, 582-584 (2012).
7. Steflitsch W, Steflitsch M. Clinical aromatherapy. Journal of Men's Health, 5, 74-85 (2008).
8. Yim VW, Ng AK, Tsang HW, Leung AY. A review on the effects of aromatherapy for patients with depressive symptoms. J. Altern. Complement. Med., 15, 187-195 (2009).
9. Moss M, Hewitt S, Moss L, Wesnes K. Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang. Int. J. Neurosci., 118, 59-77 (2008).
10. Di Stasi LC, Oliveira GP, Carvalhaes MA, Queiroz-Junior M, Tien OS, Kakinami SH, Reis MS. Medicinal plants popularly used in the Brazilian Tropical Atlantic Forest. Fitoterapia, 73, 69-91 (2002).
11. Karousou R, Balta M, Hanlidou E, Kokkini S. "Mints", smells and traditional uses in Thessaloniki (Greece) and other Mediterranean countries. J. Ethnopharmacol., 109, 248-257 (2007).
12. European Commission: SCF (Scientific Committee on Food). Opinion of the Scientific Committee on Food on pulegone and menthofuran. SCF., expressed on 2 July 2002 (2001).
13. McClanahan RH, Thomassen D, Slattery JT, Nelson SD. Metabolic activation of (R)-(+)-pulegone to a reactive enonal that covalently binds to mouse liver proteins. Chem. Res. Toxicol., 2, 349-355 (1989).
14. Bakerink JA, Gospe SM Jr, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics, 98, 944-947 (1996).
15. de Sousa DP, Nóbrega FF, de Lima MR, de Almeida RN. Pharmacological activity of (R)-(+)-pulegone, a chemical constituent of essential oils. Z. Naturforsch. C, 66, 353-359 (2011).
16. Umezu T. Evidence for dopamine involvement in ambulation promoted by pulegone in mice. Pharmacol. Biochem. Behav., 94, 497-502 (2010).
17. Koob GF, Stinus L, Le Moal M. Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav. Brain Res., 3, 341-359 (1981).
18. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci., 22, 521-527 (1999).
19. Conceição IM, Frussa-Filho R. Effects of microgram doses of haloperidol on open-field behavior in mice. Pharmacol. Biochem. Behav., 53, 833-838 (1996).
20. Mattingly BA, Rowlett JK, Ellison T, Rase K. Cocaine-induced behavioral sensitization: effects of haloperidol and SCH 23390 treatments. Pharmacol. Biochem. Behav., 53, 481-486 (1996).
21. Kita K, Shiratani T, Takenouchi K, Fukuzako H, Takigawa M. Effects of D1 and D2 dopamine receptor antagonists on cocaine-induced self-stimulation and locomotor activity in rats. Eur. Neuropsychopharmacol., 9, 1-7 (1999).
22. Baliño P, Pastor R, Aragon CM. Participation of L-type calcium channels in ethanol-induced behavioral stimulation and motor incoordination: effects of diltiazem and verapamil. Behav. Brain Res., 209, 196-204 (2010).
23. Koechling UM, Smith BR, Amit Z. Effects of GABA antagonists and habituation to novelty on ethanol-induced locomotor activity in mice. Alcohol Alcohol., 26, 315-322 (1991).
24. Pelkonen A, Yavich L. Neuromuscular pathology in mice lacking alpha-synuclein. Neurosci. Lett., 487, 350-353 (2011).
25. Bertelli JA, Mira JC. The grasping test: a simple behavioral method for objective quantitative assessment of peripheral nerve regeneration in the rat. J. Neurosci. Methods, 58, 151-155 (1995).
26. Hnasko TS, Sotak BN, Palmiter RD. Morphine reward in dopamine-deficient mice. Nature, 438, 854-857 (2005).
27. Planeta CS, DeLucia R. Involvement of dopamine receptors in diethylpropion-induced conditioning place preference. Braz. J. Med. Biol. Res., 31, 561-564 (1998).
28. nd edition, Boca Raton, FL., Chapter 4 (2009).
29. Antoniou K, Kafetzopoulos E, Papadopoulou-Daifoti Z, Hyphantis T, Marselos M. D -Amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci. Biobehav. Rev., 23, 189-196 (1998).
30. Bispo Da Silva LB, Cordellini S. Effects of diethylpropion treatment and withdrawal on aorta reactivity, endothelial factors and rat behavior. Toxicol. Appl. Pharmacol., 190, 170-176 (2003).
31. Lindquist MP, Götestam KG. Open-field behavior after intravenous amphetamine analogues in rats. Psychopharmacology (Berl.), 55, 129-133 (1977).
32. Kawasaki H, Mizuta K, Fujita T, Kumamoto E. Inhibition by menthol and its related chemicals of compound action potentials in frog sciatic nerves. Life Sci., 92, 359-367 (2013).
33. Middaugh LD, Blackwell LA, Boggan WO, Zemp JW. Brain concentrations of phenobarbital and behavioral activation or depression. Pharmacol. Biochem. Behav., 15, 723-728 (1981).
34. Galzin AM, Langer SZ. Presynaptic alpha 2-adrenoceptor antagonism by verapamil but not by diltiazem in rabbit hypothalamic slices. Br. J. Pharmacol., 78, 571-577 (1983).
35. Adachi H, Shoji T. Characteristics of the inhibition of ligand binding to serotonin receptors in rat brain membranes by verapamil. Jpn. J. Pharmacol., 41, 431-435 (1986).
36. 2+ homeostasis and causes negative inotropism in mammalian myocardium. Eur. J. Pharmacol., 672, 135-142 (2011).
37. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev., 63, 182-217 (2011).
38. Doyle GA, Yule EP. Grooming activities and freezing behaviour in relation to emotionality in albino rats. Anim. Behav., 7, 18-22 (1959).
39. Díaz-Morán S, Estanislau C, Cañete T, Blázquez G, Ráez A, Tobeña A, Fernández-Teruel A. Relationships of open-field behaviour with anxiety in the elevated zero-maze test: Focus on freezing and grooming. World Journal of Neuroscience, 4, 1-11 (2014).
40. Bouwknecht JA, Spiga F, Staub DR, Hale MW, Shekhar A, Lowry CA. Differential effects of exposure to low-light or high-light open-field on anxiety-related behaviors: relationship to c-Fos expression in serotonergic and non-serotonergic neurons in the dorsal raphe nucleus. Brain Res. Bull., 72, 32-43 (2007).
41. Louis M, Kowalski SD. Use of aromatherapy with hospice patients to decrease pain, anxiety, and depression and to promote an increased sense of well-being. Am. J. Hosp. Palliat. Care, 19, 381-386 (2002).
42. Umezu T, Morita M. Evidence for the involvement of dopamine in ambulation promoted by menthol in mice. J. Pharmacol. Sci., 91, 125-135 (2003).
43. Umezu T. Evidence for dopamine involvement in ambulation promoted by menthone in mice. Pharmacol. Biochem. Behav., 91, 315-320 (2009).
44. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl.), 92, 180-185 (1987).
45. Lister RG. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther., 46, 321-340 (1990).
46. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 14, 149-167 (1985).
47. File SE. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res., 125, 151-157 (2001).
48. Wilks LJ, File SE. Evidence for simultaneous anxiolytic and aversive effects several hours after administration of sodium phenobarbitone to the rat. Neuropsychobiology, 19, 86-89 (1988).
49. File SE. Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav. Brain Res., 21, 189-194 (1986).